AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 7 - (NewsRx Network) -- by Sonia Nichols, senior medical writer - Scientists predict therapies that use angiogenic mechanisms could some day prevent congenital malformations in the children of diabetic mothers.
These therapies would override mutations on growth factor genes normally responsible for the development of tissues within the circulatory system during embryonic growth, authors of the new research indicate.
"Major congenital malformations, including those affecting the cardiovascular system, remain the leading cause of mortality and morbidity in infants of diabetic mothers," said Emese Pinter of Yale University School of Medicine, who worked with researchers in Toronto to study the effect of hyperglycemia on growth factor signaling during embryonic development in mice.
In diabetic mothers, glucose accumulation, or hyperglycemia, acts as a toxin, causing abnormal prenatal development. Pinter and associates found that in mice excess glucose disrupted the expression of a growth factor called VEGF (vascular endothelial growth factor), which is responsible for the growth of new blood vessels. This in turn inhibited signals normally sent out by the growth factor's receptor, leading to abnormal vascular development.
These researchers found that the harmful effects of hyperglycemia could be blocked by ...